Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.2x | −6.0x | −0.5x | |
PEG Ratio | −0.24 | −0.30 | 0.00 | |
Price/Book | 4.1x | 3.6x | 2.6x | |
Price / LTM Sales | 373.7x | 67.2x | 3.2x | |
Upside (Analyst Target) | 56.2% | 96.4% | 47.6% | |
Fair Value Upside | Unlock | −8.8% | 6.1% | Unlock |